Related Experiment Video
Updated: May 11, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
Hepatitis B virus vaccination in children with steroid sensitive nephrotic syndrome: immunogenicity and safety?
N Yıldız1, Lale Sever, Ö Kasapçopur
1Istanbul University, Cerrahpaşa Medical Faculty, Department of Pediatric Nephrology, Cerrahpaşa, Istanbul, Turkey. nurdan.yildiz@marmara.edu.tr
Insights
Hepatitis B vaccination (HBVac) is less effective in children with steroid-sensitive nephrotic syndrome (SSNS) undergoing steroid therapy. Vaccination may increase relapse rates, suggesting careful consideration for HBVac in SSNS patients on steroids.
Area of Science:
- Pediatrics
- Immunology
- Nephrology
Background:
- Steroid-sensitive nephrotic syndrome (SSNS) is a common pediatric kidney disease.
- Immunization is crucial for children with SSNS, but steroid therapy can impact vaccine efficacy.
- The effectiveness and safety of Hepatitis B vaccine (HBVac) in SSNS patients require further investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of Hepatitis B vaccine (HBVac) in children with SSNS.
- To compare the immune response to HBVac in SSNS patients based on steroid usage.
- To assess the impact of HBVac on relapse rates in SSNS patients.
Main Methods:
- A study involving 41 SSNS patients and 30 controls vaccinated with Engerix-B®.
- SSNS patients were categorized into full-dose steroid users, alternate-day steroid users, and steroid non-users.
- Seroconversion rates and antibody titers (HBsAb) were measured at 6, 12, and 15 months post-vaccination.
Main Results:
- Lower seroconversion rates were observed in steroid users compared to non-users at 6 and 12 months.
- Antibody titers differed significantly between subgroups and controls at 15 months, but not between subgroups at 12 and 15 months.
- Five patients were unresponsive to HBVac, and relapse rates increased post-vaccination (p=0.002).
Conclusions:
- Hepatitis B vaccination elicits a diminished immune response in SSNS children receiving steroid therapy.
- HBVac administration may be associated with an increased risk of relapse in some SSNS patients.
- Hepatitis B vaccination is recommended for SSNS children on low-dose steroids or after steroid discontinuation.
Abstract:
We investigated the efficacy and safety of Hepatitis B vaccine (HBVac) in steroid sensitive nephrotic syndrome (SSNS) children. 41 patients with SSNS and 30 controls were vaccinated with HBVac(Engerix B(®)). Patients were divided into 3 subgroups:full dose steroid users, alternate-day steroid users and steroid non-users. Seroconversion rate was lower in steroid users than non-users at the 6th(p=0.015) and 12th(p=0.036) months. Antibody to Hepatitis B surface antigen(HBsAb) titers were significantly different between subgroups and controls at the 15th month. However, HBsAb and response rates were not different between subgroups at the 12th and 15th months (p>0.05). Five patients were unresponsive to HBVac. Relapse rates after the vaccination were higher than those in the prevaccination period (p=0.002). HBVac is less effective in producing immune response in SSNS children with steroid therapy. HBVac may trigger relapse in some patients. We recommend HBVac to SSNS children with low dose steroid therapy or after steroids are discontinued.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

